Ipsos Healthcare Receives Award from Personal Connected Health Alliance
Ipsos Healthcare, the global healthcare division of Ipsos, has been given the New Member Award by the Personal Connected Health Alliance (PCHAlliance). PCHAlliance–a non-profit organization which mobilizes stakeholders to realise the full potential of personal connected health–presented Ipsos with the award at the Fall Member Summit yesterday, an event co-located with its 9th Annual Connected Health Conference in Boston, MA. The award was received by Ipsos Healthcare’s Head of Connected Health, Reena Sangar. Commenting on its decision to recognise Ipsos, PCHAlliance said, “In its first year as a member of PCHAlliance, Ipsos Healthcare has contributed significantly to the Alliance’s efforts through its Global Connected Health Survey, Digital Doctor Survey, and new efforts related to Digital Therapeutics. Ipsos is also exploring cutting-edge approaches to studying behaviours related to personal connected health that can inform a push towards sustained use of technology.”
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
